Report28 September 2021
ACCESS ACCELERATED PUBLISHES YEAR 4 REPORT
Letter from the CEOs
From the earliest reports of the novel coronavirus in China through social distancing orders, sickness—exacerbated by chronic disease—and the tragic loss of too many lives, 2020 was a year few could have imagined and the impact will be felt by countries, communities and families for years to come.
And yet, 2020 was also a year that brought about unprecedented speed of clinical development for diagnostics, treatments and vaccines, and the rapid proliferation of digital health technologies. What has been made clear is that health is fundamental to a functioning society and only by coming together in partnership can we build and maintain strong and resilient health systems.
The successful collaborations to develop and manufacture effective COVID-19 treatments and vaccines at record speed underscore what can be accomplished when the private sector comes together. This commitment to partnership is the same one that led the biopharmaceutical industry to come together in 2017 to create Access Accelerated, a partnership that exemplifies purposeful and impactful cooperation among diverse companies that share a common belief: no one should suffer from preventable or treatable diseases.
People living with non-communicable diseases (NCDs) have faced unprecedented challenges over the past year. The urgency of the moment is why we have remained steadfast in our commitment to accelerate progress in NCD prevention, treatment and care. Through cross-industry collaboration and public-private partnerships, we continue to make progress implementing scalable and sustainable NCD solutions in low- and middle-income countries, despite the challenges brought about by the pandemic.
Access Accelerated also has been—and continues to be—an important example of how our members integrate environmental, social and governance (ESG) factors into their company strategies to continually find ways to maximize our positive impact on society. Access Accelerated demonstrates members’ ESG commitments by supporting sustainable and equitable public health solutions around the world.
For many, 2020 afforded a new window into the rigors of innovative biopharmaceutical research and development necessary to create lifesaving treatments and cures. Several, often unseen, health system components were challenged, such as ensuring the safety of frontline health workers through the availability of personal protective equipment. The pandemic also fast-tracked the adoption and impact of digital health solutions, for patients and health care professionals alike.
Download our Year 4 report to learn about our journey, our impact, and how we are accelerating the global response to non-communicable diseases.
IFPMA renounces any liability or responsibility for any damages of any nature whatsoever resulting from the use of, inability to use, and/or reliance on the material and information contained on our website. IFPMA makes no representations or warranties as to the completeness or accuracy of any of the information available on the website as well as does not provide any warranties regarding the security of the content of our website or any linked websites. IFPMA endeavours to make its best effort to keep the information accurate and updated on a regular basis, however this is not claimed to be exhaustive. IFPMA does not guarantee that the website is continuously available and error-free at all times.
We constantly analyse our website logs to improve the value of our website. We do not use this analysis to record or track any personally identifiable information of our visitors. If you are asked to provide personal information such as your name, e-mail or/and postal address when requesting information, providing feedback, registering to a newsletter, or using any other functions of the website, be assured that all such information is considered by IFPMA both private and secure. IFPMA does not share or sell your personal information to third parties. Under no circumstance will details be disclosed publicly, except in order to comply with any legal obligation. This policy reiterates that IFPMA fully appreciates the importance of online privacy and is committed to protecting your personal information.
To enable IFPMA to process any order or registration to an event, a secure online payment system may be used to process payments using credit card details. IFPMA will not be collecting or storing credit card details in our system.
Some of our web pages utilise “cookies”. A “cookie” is a small text file that may be used, for example, to collect information about web site activity. Some cookies and other technologies may serve to recall Personal Information previously indicated by a web user. Most browsers allow you to control cookies, including whether or not to accept them and how to remove them.
Some cookies are necessary for the operation of our website, if you choose to block them some aspects of the site may not work for you. Non necessary cookies are only set when you have given your explicit consent to their use. Such cookies included those set by our statistics package Google Analytics.
We are committed to privacy and support current industry initiatives to preserve individual privacy rights on the Internet. Protecting your privacy on-line is an evolving area and this website will constantly evolve to meet these demands.